These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9785195)

  • 1. The effects of gonadotropin-releasing hormone agonist on androstenedione production and follicular development during controlled ovarian hyperstimulation.
    Akaboshi K; Oda T; Yoshida J; Kohriyama S; Miyazaki T; Yoshimura Y
    J Assist Reprod Genet; 1998 Sep; 15(8):478-84. PubMed ID: 9785195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
    Agrawal R; Conway GS; Engmann L; Bekir JS; Jacobs HS
    Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization.
    San Roman GA; Surrey ES; Judd HL; Kerin JF
    Fertil Steril; 1992 Oct; 58(4):744-9. PubMed ID: 1426320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incomplete androgen and progesterone suppression following midluteal GnRHa prior to controlled ovarian hyperstimulation for IVF-ET.
    Gelety TJ; Surrey ES
    J Assist Reprod Genet; 1997 Oct; 14(9):525-30. PubMed ID: 9401871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development.
    Loumaye E; Vankrieken L; Depreester S; Psalti I; de Cooman S; Thomas K
    Fertil Steril; 1989 Jan; 51(1):105-11. PubMed ID: 2491990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
    Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
    J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization.
    MacLachlan V; Besanko M; O'Shea F; Wade H; Wood C; Trounson A; Healy DL
    N Engl J Med; 1989 May; 320(19):1233-7. PubMed ID: 2496310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of the efficiency of controlled ovarian hyperstimulation in the gonadotropin-releasing hormone agonist-suppression cycle using the initial follicle count during gonadotropin stimulation.
    Huang FJ; Chang SY; Tsai MY; Kung FT; Wu JF; Chang HW
    J Assist Reprod Genet; 2001 Feb; 18(2):91-6. PubMed ID: 11285987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of low day 3 luteinizing hormone levels on in vitro fertilization treatment outcome.
    Noci I; Maggi M; Fuzzi B; Biagiotti R; Ricci F; Marchionni M
    Gynecol Endocrinol; 2000 Oct; 14(5):321-6. PubMed ID: 11109971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
    Borm G; Mannaerts B
    Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follicular monitoring and outcome of in vitro fertilization in gonadotropin-releasing hormone-agonist-treated cycles.
    Forman RG; Robinson J; Egan D; Ross C; Gosden B; Barlow DH
    Fertil Steril; 1991 Mar; 55(3):567-73. PubMed ID: 1900482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
    Albano C; Felberbaum RE; Smitz J; Riethmüller-Winzen H; Engel J; Diedrich K; Devroey P
    Hum Reprod; 2000 Mar; 15(3):526-31. PubMed ID: 10686191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of GnRH analog for induction of the ovulatory surge of gonadotropins in patients at risk of the ovarian hyperstimulation syndrome.
    Kulikowski M; Wołczyński S; Kuczyński W; Grochowski D; Szamatowicz M
    Gynecol Endocrinol; 1995 Jun; 9(2):97-102. PubMed ID: 7502696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of gonadotrophin-releasing hormone agonist on follicular development in patients with polycystic ovary syndrome in an in-vitro fertilization and embryo transfer programme.
    Gersak K; Meden-Vrtovec H; Tomazevic T
    Hum Reprod; 1994 Sep; 9(9):1596-9. PubMed ID: 7836506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of GnRH antagonist-induced prolonged follicular phase on follicular atresia and oocyte developmental competence in vitro in superovulated heifers.
    Oussaid B; Lonergan P; Khatir H; Guler A; Monniaux D; Touze JL; Beckers JF; Cognie Y; Mermillod P
    J Reprod Fertil; 2000 Jan; 118(1):137-44. PubMed ID: 10793635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization.
    Neveu S; Hedon B; Bringer J; Chinchole JM; Arnal F; Humeau C; Cristol P; Viala JL
    Fertil Steril; 1987 Apr; 47(4):639-43. PubMed ID: 3106101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of highly purified FSH (metrodin-high purity) with pergonal for IVF superovulation.
    Bagratee JS; Lockwood G; López Bernal A; Barlow DH; Ledger WL
    J Assist Reprod Genet; 1998 Feb; 15(2):65-9. PubMed ID: 9513843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.